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ABSTRACT  
Objectives: The human genetics of HIV-2 infection and disease progression is understudied. 
Therefore, we studied the effect of variation in two genes that encode products critical to HIV 
pathogenesis and disease progression: CD4 and CD209. 
Design: This cross-sectional study consisted of 143 HIV-2, 30 HIV-1 + HIV-2 and 29 HIV-1 
infected subjects and 194 uninfected controls recruited from rural Guinea-Bissau.  
Methods: We genotyped 14 CD4 and 4 CD209 single nucleotide polymorphisms (SNPs) that 
were tested for association with HIV infection, HIV-2 plasma viral load (high vs. low), and 
CD4+ T-cell count (high vs. low).  
Results: The most significant association was between a CD4 haplotype rs11575097-
rs10849523 and high viral load (OR = 2.37, 95%CI [1.35-4.19], p = 0.001, corrected for multiple 
testing), suggesting increased genetic susceptibility to HIV-2 disease progression for individuals 
carrying the high-risk haplotype. Significant associations were also observed at a CD4 SNP 
(rs2255301) with HIV-2 infection (OR = 2.36, 95% CI [1.19-4.65], p = 0.01) and any HIV 
infection (OR = 2.50, 95% CI [1.34-4.69], p = 0.004).  
Conclusions: Our results support a role of CD4 polymorphisms in HIV-2 infection, in agreement 
with recent data showing that CD4 gene variants increase risk to HIV-1 in Kenyan female sex 
workers. These findings support at least some commonality in HIV-1 and HIV-2 susceptibility. 
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CD4 SNPs associate with HIV-2 infection in Guinea-Bissau (final version) 4 
INTRODUCTION 
Human immunodeficiency virus (HIV) infection rates vary across Africa, with the highest 
adult prevalences in southern and eastern regions (up to approximately 30%) and the lowest rates 
in northern and western regions (0.1-5.0%).1 HIV-1 is global, but HIV-2 occurs primarily in 
West Africa.2,3 In Caio’, rural Guinea-Bissau, where we performed our cohort study, we 
observed an increasing prevalence of HIV-1 and a decreasing prevalence of HIV-2.4 Another 
study from an urban area in Guinea-Bissau confirmed the trends.5  
Despite characteristics shared with HIV-1,6 HIV-2 displays differences, such as lower 
mother to child transmission rates (1-4% vs. 20-40%), lower sexual transmission (1/3 to 1/4 that 
of HIV-1), lower plasma viral load (0-1000 vs. 10,000-100,000 copies/ml), slower CD4 decline, 
lower likelihood of progression to AIDS and generally slower progression to AIDS when it does 
occur (although fast progressors have been described).6 However, clinical AIDS from HIV-2 is 
similar to HIV-1 with no substantial difference in mortality.7 
The host genetics of HIV-1 has received considerable attention and reported associations 
include HLA-B, HLA-C, CCR2, CCR5, CCL5 (RANTES) and CCL3L1 variants.8-16 Host genetics 
of HIV-2 is almost completely unstudied. One study from Senegal described an association of 
HLA-B53 with increased risk of HIV-2 disease progression, consistent with previous findings on 
HIV-1 in Caucasians.17 Ali and colleagues studied the gene encoding α (1,2) fucosyltransferase 
(FUT2) in HIV-1, HIV-2 and dually infected Senegalese women, and found a suggestive 
association with secretor status in HIV-1 but not in HIV-2 infection.18  
Although it has been reported that HIV-2 infection protects against HIV-1 infection in 
vitro and to some extent in vivo (summarized by3), the epidemiological evidence does not 
support such an effect.19  
A large number of biologically plausible candidate genes potentially exist for the study of 
host genetic factors in HIV infection pathogenesis and disease progression. Our report focuses 
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on two molecules that play central roles in critical pathophysiological processes relevant to HIV: 
T-cell antigen T4/Leu3 (encoded by CD4) and dendritic cell-specific ICAM3-grabbing 
nonintegrin (DC-SIGN, encoded by CD209). We genotyped single nucleotide polymorphisms 
(SNPs) in CD4 and CD209 in a cohort of HIV-1, HIV-2 and dually infected individuals from 
Guinea-Bissau.  
 
MATERIALS AND METHODS 
Study Area and Subjects 
The study was conducted in Caio’, a rural area in north-western Guinea-Bissau, comprising nine 
small, predominantly Manjago settlements (98% of subjects studied). Ethnicity was thus not 
adjusted for in the analyses. Since 1989 several HIV serosurveys have been conducted in this 
area.19,20 All HIV infected persons and a similar number of age-, sex- and settlement-matched 
HIV uninfected controls were recruited for a cohort study, examined and sampled in 1991, 1996, 
and 2003. Our study is based on the 2003 study round, which comprised 547 eligible subjects. 
None of the study participants were on antiretroviral therapy (ART). As with any seroprevalent 
cohort or cross-sectional study, the HIV subjects are by definition survivors, and in this cohort 
there is an effect of HIV status on survival.21 This study was approved by the MRC 
Laboratories/Gambia Government Joint Ethics Committee, the London School of Hygiene & 
Tropical Medicine Ethics Committee, and the Research Committee of the Ministry of Health of 
Guinea-Bissau.  
All participants gave informed written consent.   
 
Laboratory methods 
Sample preparation. An 8 ml blood sample was taken from a cubitous vein in EDTA 
tubes. Two ml of the sample were used for routine laboratory tests and six ml were centrifuged 
CD4 SNPs associate with HIV-2 infection in Guinea-Bissau (final version) 6 
for 5 minutes at 2000 rpm, the plasma was drawn off, divided into three aliquots and frozen in 
liquid nitrogen. Lysis buffer was added to the cellular fraction for later DNA purification. Frozen 
plasma and samples in lysis buffer were transported to the MRC Laboratories in Fajara (The 
Gambia), where further analyses were performed and the DNA extractions were completed.  
HIV sero-diagnosis. Plasma samples were screened for HIV antibodies using the ICE 
HIV1.2.0 assay (Abbott Murex Diagnostics, Dartford, UK). Positive samples were tested using 
two monospecific ELISA's: Wellcozyme HIV Recombinant I (Abbott Murex) and ICEHIV-2 
(Abbott Murex) to differentiate between HIV-1 and HIV-2 infection. If one mono-specific 
ELISA was positive and the other negative, an individual was characterized as singly infected. In 
case of dual reactivity, the sample was diluted (1:10) and subjected to re-testing by the same two 
mono-specific ELISAs.  
HIV diagnostic PCR. All samples that showed dual reactivity in the two mono-specific 
ELISA's (undiluted) were subjected to separate diagnostic nested PCRs for HIV-1 and HIV-2 in 
order to confirm dual infection. Both PCRs used primers targeted to highly conserved regions of 
the LTR of the HIV-1 or HIV-2 genome22,23  and were used to amplify pro-viral DNA extracted 
from whole blood samples. Each reaction contained 600 ng of DNA, equivalent to 100,000 cells. 
Specific products were detected on ethidium bromide stained agarose gels.  
HIV viral load. Virus load was measured using an in-house assay. Amplifications included 
an internal molecular control and products were quantified in an enzyme-linked oligonucleotide 
assay (ELONA).22 
Lymphocyte subsets. The routine method was to use rapid field adapted Simultest 
monoclonal antibodies (Becton Dickinson, Erembodegem, Belgium) to stain and fix the cells 
using the Q-Prep machine (Beckman Coulter Ltd, High Wycombe, UK) in the field laboratory. A 
10 µL blood sample was rapidly processed with Simultest CD3/CD4/CD8 conjugated antibodies 
(Beckton Dickinson, Erembodegem, Belgium) and fixed. The samples were then transported 
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overland to the Laboratório Nacional de Saúde Pública in Bissau, where they were analyzed 
using FACStrack and SimulSet software (Becton Dickinson, San Jose, CA, USA). FACS results 
were regarded as invalid if the CD3 % of the two runs were more than 10% different from each 
other, or if the mean of the two CD3 % was < 45%, or if the sum of CD4 % and CD8 % was 
more than 10% different from the mean CD3 %. 
A second, back-up method for lymphocyte subset measuring was also in place. For this 
method, 100 μl “TransFix” solution (NEQAS, Sheffield, UK)24 was added to 500 μl fresh blood 
and roller-mixed for 5 minutes, after which the sample was kept in a refrigerator at 4 ºC and 
transported to the MRC Laboratories in Fajara, The Gambia. When the routine method failed, the 
transfixed samples were stained with fluorochrome-conjugated monoclonal antibodies manually 
rather than by Q-Prep, and analyzed in the FACScalibur, using the MultiSet software (Becton 
Dickinson, Erembodegem, Belgium). Results were regarded as invalid if the CD3 % was < 45%, 
or if the sum of CD4 % and CD8 % was more than 10% different from the mean CD3 %. 
In order to investigate whether the results of the two methods (routine and back-up) were 
comparable, 13 samples were processed using both methods and results compared. The 
agreement was excellent (r2 = 0.89 for CD4 %). In addition, a Bland and Altman test25 was 
performed to compare the two methods and indicated no difference between them (p = 0.3).  
DNA extraction and genotyping. DNA was extracted from the packed blood cells, using 
the Puregene DNA extraction kit (Flowgen, Ashby de la Zouch, UK) or a standard salting-out 
procedure. SNP selection was based on physical location within the gene, minor allele frequency 
(MAF) (> 0.10 in the Yoruba population of the HapMap dataset (http://www.hapmap.org), with 
exception of CD4 rs11064419), and assay availability. Chromosome band, SNP rs number, 
marker alleles, reference allele frequencies, amino acid change, and marker function (if known) 
are reported in Table 1 and were identified using the SNPper database (http://snpper.chip.org), 
based on NCBI Build 35.1. CD209 markers were genotyped by standard TaqMan SNP assays 
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(ABI, Applera International Inc, Foster City, CA, USA) in 10 μl reaction volume, using the 
Rotor-Gene 3000 (Corbett Robotics Pty Ltd, Brisbane, Queensland, Australia) and the ABI 7500 
real-time PCR systems. Fluorescence curves were analyzed with the Rotor-Gene Software 
version 6 and the 7500 Sequence Detection. CD4 genotyping was carried out using the 
Sequenom hME Mass-Array primer extension assay (http://www.sequenom.de/)26 under 
standard conditions. Primer sequences for CD4 genotyping are shown in the supplementary 
materials (Table 1, Supplemental Content). 
 
Statistical Methods 
STATA 9.0 statistical software (STATA 9, College Station, TX, 2007) was used to 
perform the statistical analyses including the Shapiro-Wilk test, logistic regression and haplotype 
Odds Ratio (OR) and 95% Confidence Interval (CI) calculation. 
Demographic data. Chi square tests were used to compare HIV status by gender, and t-
tests were used to test for differences in the mean ages of study participants between HIV groups 
and controls. Age was tested for normality, using both visual inspection and Shapiro-Wilk tests, 
age did not differ from normality and as a result a t-test was performed. 
Dichotomous analyses of HIV groups versus controls. Tests for deviation from Hardy 
Weinberg Equilibrium (HWE) were performed using Powermarker software.27,28 Tests for allele 
and genotype associations were also performed with Powermarker software. Statistical 
significance for these analyses was determined using Fisher’s exact tests. Logistic regression was 
performed on all SNPs with statistically significant allele or genotype tests of association 
modelling additive, dominant, and recessive models with the minor alleles as the risk allele. No 
correction for multiple comparisons was made at this stage (for further details see below). 
Pairwise linkage disequilibrium (LD) was characterized and haplotype frequencies were 
calculated using Powermarker27,28 and Haploview29 statistical softwares. Standard summary 
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statistics D’ and r2 were calculated using Haploview.29 Haplotype blocks were assigned, using 
the D’ confidence interval algorithm created by Gabriel et al.30 Both Powermarker and 
Haploview use an EM algorithm to determine haplotype frequency distributions when phase is 
unknown.  
The Powermarker haplotype trend analysis was performed for CD4 and CD209 using 2- 
and 3-SNP sliding windows. This analysis is a regression approach to test haplotype-trait 
association.27,28 The test for association uses an F test for a specialized additive model. Only 
haplotypes with a minimum of 5% frequency were considered in the analysis. Haplotype trend 
analysis produces global p values for tests of haplotype associations and not haplotype specific p 
values. P values were calculated using the permutation option (1000 permutations) to obtain a 
more reliable empirical p value. Odds Ratios (OR) and 95% confidence intervals (CI) for 
haplotype analysis were calculated for each individual haplotype with the referent being the most 
frequent haplotype. We used permutation tests to correct for multiple testing. 
CD4 count and plasma viral load for HIV-2 analyses. CD4 count (cells/μl) and plasma 
viral load for HIV-2 (pvlhiv2) (copies/ml) were dichotomized into high and low groups for the 
analysis of associations within the group of HIV-2 infected subjects. The high and low groups 
for CD4 were ≥ 500 cells/μl versus < 500 cells/μl; the cut-off for CD4 is the lower limit of 
normal CD4 counts. The high and low groups for pvlhiv2 were ≥ 1000 copies/ml versus < 1000 
copies/ml; this cut-off was based on an earlier study that showed that subjects with a viral load 
below this threshold (and with a normal CD4 count) had a normal life expectancy, i.e. similar to 
uninfected controls.31 These data were analyzed for allele and genotype associations with 
Fisher’s exact tests using Powermarker.27,28   
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RESULTS 
Subjects 
Of the 547 eligible subjects, 26 subjects died prior to enrollment, two had moved away 
from the area permanently, 97 subjects were away temporarily, and 15 refused to participate. All 
remaining 407 subjects gave a medical history and had a physical examination. Of these, 402 
provided blood samples. Five of these samples did not yield usable DNA and clinical data was 
lacking for one additional subject, leaving 396 subjects for genetic analyses: 202 HIV-infected 
cases and 194 controls. The distribution of HIV-1, HIV-2 and dual infection status among cases 
was 29 (14.4%), 143 (70.8%), and 30 (14.9%), respectively. Analyses of demographic variables 
(Table 2, Supplemental Content) showed a difference in age between groups, with the HIV-1 
group being significantly younger (p < 0.001). No statistically significant differences were 
observed between groups with respect to gender. 
Dichotomous association analyses (HIV groups 1, 2, and dual infection versus controls) 
HWE was tested in controls and there was one significant deviation from HWE at marker 
rs874627 (p<1.00x10-3). Tests for HWE revealed significant deviations from expected in several, 
but not all, HIV groups including: rs874627, rs2255301, rs1045261, rs1055141, rs8105483, 
rs2071081 and rs3213427 (Table 3, Supplemental Content). Single locus tests identified 
associations in CD4 at rs2255301, rs2886398, rs11064419, rs874627, rs2071081 with alleles 
and/or genotypes (Table 2; Table 3, Supplemental Content).  
Additive, dominant and recessive logistic regression models for the SNPs that showed the 
strongest associations are presented in Table 3. For SNP rs2255301 the C/C&C/T vs. T/T had the 
strongest effect size across all outcomes: for HIV-2 (OR = 2.36 [CI 1.19-4.65]), dual infection 
(OR = 4.14 [CI 1.19-14.39]), and all HIV (OR = 2.50 [CI 1.34-4.69]). For SNP rs2071081 the 
strongest effect size was for the A/A&A/C vs. C/C model for HIV-1 (OR = 5.60 [CI 1.38-22.71]) 
and A/A vs. A/C&C/C5 for all HIV (OR = 1.58 [CI 0.94-2.67]) (Table 3). 
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Haplotype trend regression analysis revealed a significant 3 marker haplotype association 
(rs8105483-rs2287886-rs4804803) in CD209 (p = 0.03) with HIV-1 (Table 4, Supplemental 
Content). No individual haplotypes associations were detected when comparing each haplotype 
in cases and controls to the referent (most frequent) haplotype; however CGG was marginally 
protective, (OR = 0.67 [CI 0.43-1.03] (p = 0.06)). There was no strong evidence of haplotype 
association for the CD4 gene. 
Analyses of HIV-2 examining CD4 count and plasma viral load in HIV-2 (pvlhiv2) 
CD4 count significantly associated with both allelic and genotypic variation at CD209 
rs8105483 in patients who were HIV-2 infected (allele p = 0.02 and genotype p = 0.05). In 
analyses of plasma viral load, CD4 markers rs11575097 (p = 0.03) and rs10849523 (p = 0.02) 
had significant allelic associations and rs11575097 had a significant genotypic association (p = 
0.04). 
Haplotype analyses showed a significant association for CD209 rs8105483-rs2287886 
(global p = 0.02) (Table 4) with CD4 count. Two individual haplotypes for these markers 
showed the following association: G-G (OR = 1.98 [CI 1.02-3.98] (p = 0.03)) with a frequency 
of 0.34 for the high CD4 count group and 0.18 for the low CD4 count group. The G-A haplotype 
had a frequency of 0.00 in the high CD4 count group and 0.10 in the low group; therefore, an OR 
was not calculated. Haplotype analyses assessing HIV-2 plasma viral load also identified a 
significant two-marker haplotype for markers rs11575097-rs10849523 (global p = 0.004) (Table 
4). Haplotype G-G was the only significantly associated haplotype, with an OR = 2.37 [CI 1.35-
4.19] and a p = 0.001. The frequency of G-G was 0.39 in the high group and 0.20 in the low 
group.  
 
DISCUSSION 
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In the present study we examined eighteen SNPs in two host candidate genes, CD4 and 
CD209, for association with HIV status, as well as plasma viral load and CD4 count in subjects 
infected with HIV-2. We observed statistically significant associations between individual CD4 
polymorphisms and HIV-2 status, HIV-2 plasma viral load and dual infection (the latter group 
being small). Although we did not observe evidence for disease status association with single 
CD209 SNPs, we did observe some evidence for haplotype specific associations in analyses of 
the HIV-1 infected group compared to control groups (however this was based on small numbers 
of HIV-1 infecteds). More convincingly, we found evidence for CD4 haplotype frequency 
differences between HIV-2 individuals with high and low viral load (OR = 2.37, 95%CI [1.35-
4.19], p = 0.001).  
CD4 is essential to immune regulation; it acts as an accessory protein for MHC class-II 
antigen and is involved in T-cell receptor interaction. CD4 is also a primary receptor for both 
HIV-1 and HIV-2, even if viral isolates of HIV-2 can infect T cells in the absence of CD4, using 
the chemokine receptor Fusin/CXCR4.32 There is some evidence that laboratory-adapted CD4-
independent HIV-1 infection also exists.33 Although co-receptors are required for virus entry into 
the host cell and HIV-2 can use a wider range of co-receptors than HIV-1,3 given the CD4 
receptor’s major role, the CD4 gene is an obvious candidate for “susceptibility to HIV 
infection”. Nonetheless, few studies have investigated the role of host genetic variation in CD4.  
A recent study examining Kenyan female commercial sex workers34 observed an 
association between HIV-1 infection and the CD4 variant C868T. The C868T variant encodes a 
non-synonymous substitution at amino acid residue 240 of Arginine (R) to Tryptophan (W) 
known to change the tertiary structure of CD4 (the so called “CD4-Trp240” receptor), which 
could alter either the binding HIV to CD4 or CD4–dependent activation of T cells.35-37 Oyugi et 
al (2009) showed that the minor allele of C868T is associated with an increased susceptibility to 
HIV-1 infection.34 We did not type this specific SNP in our cohort; however, we did observe an 
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association with dual infection (p = 0.04) at a SNP (rs11064419) that is located less than 40 bp 
from C868T. These two SNPs are in strong LD based on HapMap data and our own data on 
controls suggests an LD block in this region (Figure 1, Supplemental Content). Since the other 
study did not test for association with HIV-2 or dual infection, their results cannot be directly 
compared to ours. Nonetheless, association within this small region of the CD4 gene with both 
HIV-1 and HIV-2 in the two studies suggests that a variant in this region is of functional 
importance with respect to susceptibility to infection.  
In our study, significant associations, both allelic and genotypic, were observed between 
SNP rs2255301 and infection status (Table 2). This SNP is located in intron 2, < 200 bases from 
exon 2 and in the boundary with exon 3. Both of these exons encode the amino-terminal D1 
domain of CD4, an Ig variable (V)-like domain that binds with high affinity to the gp120 
glycoprotein in the viral envelope.38 Although we did not find evidence for significant LD 
between rs2255301 and other SNPs we typed around the D1 coding sequence, it is reasonable to 
hypothesize that rs2255301 is in LD with a functional, but uncharacterised, variation affecting 
this domain. Our lack of LD in this region is not surprising given the fact that our SNPs in this 
region are more than 4000 bp from rs2255301. However, an association with high plasma viral 
load (hence suggesting faster clinical progression) was detected with the rs11575097-
rs10849523 G-G haplotype (Table 4) in intron 2, further reinforcing the idea that variation in this 
part of the gene is linked to increased susceptibility. Functional variation in CD4 (and D1 in 
particular) could have a significant impact on susceptibility to HIV, as suggested by evidence of 
recent positive selection of intragenic polymorphisms.39 However, a correlation between variants 
showing signatures of positive selection and those predicting risk has yet to be found.39 This may 
be an artefact of how recent the pressure of HIV may be on this gene, the fact that only a 
minority of the population is exposed, and that different parts of the gene are susceptible to 
different selection pressures (from one or more infectious agents).  
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CD209 encodes the dendritic cell-specific ICAM3-grabbing nonintegrin (DC-SIGN), 
present on both macrophages and dendritic cells (DCs) and it belongs to the C-type lectin 
receptor family. HIV can subvert DC defense mechanisms and escape immune surveillance, 
allowing the virus to enter T cells, thus leading to infection of these cells.40 Reports have 
associated variation in CD209 with HIV-1 susceptibility, but findings from different studies and 
different ethnic groups are inconsistent and comparative genomics data from chimpanzees are 
unsupportive.41-48 
The CD209 role in transporting the virus via immature DCs from the periphery to lymph 
nodes, where CD4 cells would be activated and infected, could explain a link between CD209 
genetic variation and CD4 count. In our dataset the rs8105483-rs2287886 (in LD, Figure 2, 
Supplemental Content) G-G haplotype was associated with protection from disease (i.e. with 
“high” CD4 count; p = 0.03) however the "low count" CD4 subset was based on only five 
subjects carrying the G-A risk haplotype while no G-A were observed in the "high count" group. 
Given the small numbers no clear conclusion can be drawn. 
Although we did not explicitly correct for multiple tests for single SNPs we did calculate 
empirical p-values by using permutation testing of haplotypes; similar size effect and level of 
significance were detected when haplotypes included positively associated single SNPs. This 
suggests that, despite no correction for multiple testing for single markers, the results are reliable 
and merit follow-up. CD4 rs874627 deviated from HWE in controls, however, this SNP was not 
part of the haplotype associated with viral load in the HIV-2 group. 
This study implicates CD4 as susceptibility gene for HIV-2 infection in West Africans 
from Guinea-Bissau and, to our knowledge, is the first study examining the role of CD4 and 
CD209 variants in HIV-2 infection. The effect of CD4 polymorphisms in our HIV-2 cohort, in 
addition to the association reported in the HIV-1 cohort from Kenya,31 suggests that sequence 
variation in CD4 plays a role at a fundamental biological level in the interaction between HIV 
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and host and that there may be some commonality in HIV-1 and HIV-2 susceptibility. 
Elucidation of the precise role this gene plays in HIV susceptibility depends on isolating 
functional variants that may explain the phenotypic effect. 
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Table 1.  Marker information 
Gene SNP rs# 
Database 
Alleles 
Reference 
Allele 
Reference allele 
frequency in 
HapMap YRI1 
Function 
Amino  
Acid Change
CD4 
Chr 12p13.31 
rs2855534 C/G G 0.37 Promoter - 
rs2707209 C/T C 0.42 Intron - 
rs2255301 C/T T 0.38 Intron (boundary) - 
rs2886398 A/G  N/A Intron - 
rs7957426 A/G G 0.89 Intron - 
rs11575097 C/G  N/A Intron - 
rs10849523 C/G C 0.66 Intron (boundary) - 
rs3782736 A/C C 0.67 Intron - 
rs11064419 C/T T 0.96 Coding exon F227S 
rs1055141 C/T T 0.21 Coding exon S341S 
rs3213427 G/T T 0.77 3' UTR - 
rs1045261 C/T T 0.76 3' UTR - 
rs874627 A/C G 0.54 Downstream - 
rs2071081 A/C A 0.85 Downstream - 
CD209 
Chr 19q13.2 
rs4804803 A/G G N/A Promoter - 
rs2287886 A/G A 0.2 Promoter - 
rs8105483 C/G C 0.74 Intron - 
rs11465413 A/T A 0.48 3' UTR - 
1 YRI: HapMap Yoruba data 
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Table 2.  Statistically significant single marker analysis within each HIV subgroup and all groups combined 
 
Gene Marker MA3 
MAF4 
controls 
(N=194) 
MAF Cases by HIV Group Allelic association p Value Genotypic association p Value 
1 2 Dual All 
1 2 Dual All 1 2 Dual All 
(N=29) (N=143) (N=30) (N=202) 
CD4 
rs22553012 T 0.41 0.45 0.47 0.29 0.45 0.62 0.27 0.008 0.09 0.14 0.02 0.005 0.008 
rs2886398 A 0.34 0.35 0.36 0.5 0.36 0.73 0.54 0.05 0.32 0.9 0.48 0.11 0.51 
rs11064419 C 0.05 0.02 0.06 0.12 0.05 0.47 0.51 0.04 0.58 0.46 0.41 0.15 0.44 
rs8746271,2 G 0.2 0.29 0.16 0.5 0.21 0.2 0.59 0.04** 0.64 0.43 0.59 0.13 0.56 
rs20710812 C 0.15 0.26 0.23 0.11 0.19 0.09 0.05 0.58 0.05 0.03 0.12 0.84 0.18 
1This marker deviated from HWE in the controls: rs874627 (p<1.00x10-3). 2These markers had significant deviations (p value ≤ 0.05) from HWE in one of the 
HIV groups: rs874627 (control group, p < 1.00x10-3; HIV-1, p = 0.002: HIV-2, p < 1.00x10-3), rs2255301 (all HIV group, p = 0.01; HIV-2, p = 0.01), rs1045261 
(all HIV group, p = 0.01; HIV-2, p = 0.04); rs1055141 (all HIV group, p = 0.04; HIV-2, p = 0.02), rs8105483 (all HIV group, p = 0.04), rs2071081 (HIV-1, p = 
0.02), and rs3213427 (HIV-2, p = 0.001). 3MA-minor allele 4MAF-minor allele frequency * In bold are all statistically significant associations (p ≤ 0.05). 
Associations with HIV-2 and dual infection should be interpreted with caution based on the small sample size for these groups and because rs874627 was out of 
HWE in both cases and controls (although this may be due to chance). 
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Table 3.   Associations between two single loci (CD4 SNPs rs2255301 and rs2071081) 
and HIV infection, based on additive, dominant and recessive models 
 
Marker Outcome Model OR1 [95% CI]2 p Value 
rs2255301 
HIV-2  
C/C (referent), C/T, T/T3 1.25 0.86-1.84 0.25 
C/C&C/T (referent) vs. T/T4   2.36 1.19-4.65 0.01 
C/C (referent) vs. CT&T/T5 0.9 0.50-1.61 0.72 
Dual 
HIV  
C/C (referent), C/T, T/T3 4.08 1.51-11.03 0.006 
C/C&C/T (referent) vs. T/T4   4.14 1.19-14.39 0.026 
C/C (referent) vs. C/T&T/T5,6 - - - 
All HIV  
C/C (referent), C/T, T/T3 1.36 0.96-1.92 0.09 
C/C&C/T (referent) vs. T/T4   2.5 1.34-4.69 0.004 
C/C (referent) vs. C/T&T/T5 1.3 0.60-1.76 0.91 
rs2071081 
HIV-1 
A/A (referent), A/C, C/C3 1.75 0.89-3.42 0.1 
A/A&A/C (referent) vs. C/C4 5.6 1.38-22.71 0.02 
A/A (referent) vs. A/C &C/C5 1.46 0.57-3.72 0.43 
All HIV 
A/A (referent), A/C, C/C3 1.49 0.98-2.27 0.06 
A/A&A/C (referent) vs. C/C4 2.01 0.66-6.17 0.22 
A/A (referent) vs. A/C&C/C5 1.58 0.94-2.67 0.08 
1OR-odds ratio 2CI-confidence interval 3Additive model 4Dominant model 5Recessive model 6The OR for 
the dual infection dominant model could not be calculated because there were no cases with the referent 
genotype (C/C). *In bold are all statistically significant associations (p ≤ 0.05) 
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Table 4.   Associations between haplotypes and CD4 count or plasma viral load among 
HIV-2 infected subjects 
 
Outcome Haplotype 
Global 
p 
Value 
Markers 
Relative Frequency 
of haplotype 
OR [95% CI] p Value High Low 
CD4 count1 
High n = 88 
Low n = 49 
CD209 
rs8105483- rs2287886 
0.02 C-G 0.48 0.51 (Baseline) - - 
 G-G 0.34 0.18 1.98 1.02-3.98 0.03 
 C-A 0.18 0.21 0.95 0.47-1.96 0.88 
 G-A 0 0.1 - - 0.001 
Plasma Viral Load2 
High n = 71 
Low n = 72 
 
CD4 
rs11575097- rs10849523 ** 
0.004 G-C 0.6 0.74 (Baseline) - - 
 G-G 0.39 0.2 2.37 1.35-4.19 0.001 
 C-G 0.01 0.04 0.25 0.01-2.30 0.18 
 C-C 0 0.02 - - 0.12 
 
 
1 CD4 count: ≥ 500 cells/μl (high) versus < 500 cells/μl (low) 
2 Plasma viral load: ≥ 1000 copies/ml (high) versus < 1000 copies/ml (low) 
*In bold are all statistically significant associations (p ≤ 0.05) 
**Also significant was the three marker haplotype consisting of rs11575097- rs10849523- rs3782736 (p = 
0.009), however, this was not the strongest window and therefore those results are not presented. 
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Supplemental Figure Legends 
 
Supplemental Figure 1.  CD4 HIV-2 subgroup and control haplotype linkage 
disequilibrium (r2 and D’) plots  
Linkage disequilibrium (LD) plots characterizing haplotype blocks in CD4 in Guinea Bissau. All 
figures are oriented 5’ to 3’, right to left, relative to the gene orientation on the minus strand. In 
the first column are LD plots for pairwise D’ between SNPs (control group A, HIV-2 subgroup 
C) and in the second column are LD plots for pairwise r2 between SNPs (control group B, HIV-2 
subgroup D). Both r2 and D’ values are indicated in percentages within squares in the LD plot. 
Strong LD is indicated by dark gray/red, while light gray/pink and white indicate uninformative 
and low confidence values, respectively. LD Blocks were created using the default algorithm in 
HaploView program, version 4.1. 
 
Supplemental Figure 2.  CD209 HIV-1 and HIV-2 subgroup and control haplotype linkage 
disequilibrium (r2 and D’) plots 
Linkage disequilibrium (LD) plots characterizing haplotype blocks in CD4 in Guinea Bissau. LD 
plots for pairwise r2 and for pairwise D’ between SNPs for control group (A, B), for HIV-1 
subgroup (C, D) and HIV-2 subgroup (E, F). Please refer to Supplemental Figure 1 legend for a 
description of the colour scheme used to define pairwise LD between SNPs. The haplotype 
blocks were created using the HaploView program, version 4.1. 
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Supplemental Table 1.  SNP primer details 
Gene SNP_ID Fwd primer Rev primer Extension primer 
CD4 rs2855534 ACGTTGGATGTGCCATCTTTTTCTTGCCGC ACGTTGGATGGCCAAAGTCAAGGGAAAAAG GCTTAAATCAGGAGTCAAA 
CD4 rs2707209 ACGTTGGATGATCAGTGACTTTCGCTCCTC ACGTTGGATGGACATAGAGAGAGGACTTGG GGCTAACTTAAGCCAAATT 
CD4 rs2255301 ACGTTGGATGAAAGGCAAAGGTGGAGGATG ACGTTGGATGAGGAGCGCTAAGTGGAAAAG AGGAGTCAGGTCTCA 
CD4 rs2886398 ACGTTGGATGGTCATCCACAAATAGGAACAG ACGTTGGATGTGCCAGTGCAATAAGGCAAG AGGAAAACTGATCAGAAAG 
CD4 rs7957426 ACGTTGGATGTTCTCCACATCCTCATCAGC ACGTTGGATGAAACCACAATAGGCTATCAC AATAGGCTATCACTAAACCTATCA 
CD4 rs11575097 ACGTTGGATGAACTCCTGCCCTCAGGTGAT ACGTTGGATGAAAAGAGGTATGGGCCTGTG CGCCTGTAATCCCAGCA 
CD4 rs10849523 ACGTTGGATGCGATCATTCAGCTTGGATGG ACGTTGGATGCATTCTCTTGCCAGAGGTGC GCGCCTCAGTCCCCC 
CD4 rs3782736 ACGTTGGATGTGAAATCCTGGTTCTGCCAC ACGTTGGATGTCACAGAGGCTGAAACCAAG GAGGTTTAGTAACTCACCCAAG 
CD4 rs11064419 ACGTTGGATGCCTCCAGCATAGTCTATAAG ACGTTGGATGCACTGCCCGTCAGCTTTTCA CCCGTCAGCTTTTCAACTGTA 
CD4 rs1055141 ACGTTGGATGATTTGACCTGTGAGGTGTGG ACGTTGGATGACCTTTGCCTCCTTGTTCTC CTTGTTCTCCAGTTTCAA 
CD4 rs3213427 ACGTTGGATGTCCACGCCATTTCCTTTTCC ACGTTGGATGTGGGATCCAAATGAGCAGTG GGAGAGGGTCAGAGAGAAAT 
CD4 rs1045261 ACGTTGGATGTGTGCAGAACCTCCTGGAAG ACGTTGGATGCTGGCACAATCACCTTTGAG CCTTTGAGGTCCCTT 
CD4 rs874627 ACGTTGGATGAAGAGTGCTCAGAGACCATG ACGTTGGATGTTCAGCCGCAGACCTCTCAT TTCCCTCCTTCCCTC 
CD4 rs2071081 ACGTTGGATGTTCTCCAGTGTCTGTTAGGC ACGTTGGATGCCTCTCTTGCTATAGCTTTC CTTTCTTTCACCCAGCTC 
CD209 
rs11465413, 
rs8105483, 
rs2287886, 
rs4804803 
CD209 SNPs were genotyped employing off-the-shelf TaqMan SNP assays (ABI, Applera International Inc, Foster City, CA, USA). 
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Supplemental Table 2.  Age and gender of study subjects, by HIV status 
HIV group 
Gender Age 
Female Male P 1 
Mean 
(yrs) 
SD3 P 2 
All HIV groups 139 (68.8%) 63 (31.2%) 0.34 52.5 15.3 0.80 
HIV-1 18 (62.1%) 11 (37.9%) 0.21 39.4 10.4 0.0001
HIV-2 96 (67.1%) 47 (32.9%) 0.23 56.1 15.0 0.96 
HIV-1 & HIV-2 infection 25 83.3%) 5 (16.7%) 0.24 48.2 12.2 0.16 
Control group 142 (73.2%) 52 (26.8%)  52.9 17.9  
 
1P values from chi square tests comparing HIV group to control group 
2P values from t-test comparing mean ages between HIV group and control group 
3SD is the standard deviation. 
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Supplemental Table 3.  Single marker analysis within each HIV subgroup and all HIV subgroups combined 
Allelic 
Association p Value
Genotypic 
Association p ValueGene Marker MA3
MAF4 
Controls
MAF Cases by HIV Group 
  
1 2 Dual All 1 2 Dual All 1 2 Dual All 
CD4 
rs2855534 G 0.33 0.40 0.35 0.18 0.34 0.33 0.69 0.13 0.78 0.40 0.78 0.13 0.97 
rs2707209 C 0.40 0.39 0.40 0.29 0.39 0.87 0.93 0.21 0.76 1.00 0.30 0.51 0.4 
rs22553012 T 0.41 0.45 0.47 0.29 0.45 0.62 0.27 0.008 0.09 0.14 0.02 0.005 0.008
rs2886398 A 0.34 0.35 0.36 0.50 0.36 0.73 0.54 0.05 0.32 0.90 0.48 0.11 0.51 
rs7957426 A 0.10 0.08 0.08 0.12 0.09 0.79 0.55 0.76 0.61 1.00 0.53 0.59 0.73 
rs11575097 C 0.02 0.04 0.04 0.02 0.03 0.30 0.29 0.60 0.34 0.31 0.28 0.59 0.22 
rs10849523 G 0.29 0.28 0.31 0.36 0.30 1.00 0.55 0.50 0.52 0.75 0.80 0.44 0.86 
rs3782736 A 0.44 0.44 0.41 0.38 0.43 0.88 0.50 0.61 0.46 0.49 0.29 0.56 0.20 
rs11064419 C 0.05 0.02 0.06 0.12 0.05 0.47 0.51 0.04 0.58 0.46 0.41 0.15 0.44 
rs10551412 T 0.12 0.14 0.17 0.12 0.14 0.44 0.10 1.00 0.13 0.52 0.23 0.61 0.39 
rs32134272 C 0.13 0.15 0.16 0.11 0.14 0.65 0.33 1.00 0.57 0.55 0.40 0.81 0.68 
rs10452612 C 0.30 1.00 0.40 - 0.46 0.07 1.00 - 0.25 0.59 1.00 - 0.38 
rs8746271,2 G 0.20 0.29 0.16 0.50 0.21 0.20 0.59 0.04 0.64 0.43 0.59 0.13 0.56 
rs20710812 C 0.15 0.26 0.23 0.11 0.19 0.09 0.05 0.58 0.05 0.03 0.12 0.84 0.18 
CD209
rs11465413 A 0.44 0.36 0.41 0.42 0.42 0.26 0.40 0.67 0.34 0.57 0.71 0.58 0.54 
rs81054832 G 0.32 0.33 0.33 0.40 0.33 0.78 0.73 0.24 0.49 0.18 0.29 0.18 0.11 
rs2287886 A 0.26 0.17 0.22 0.25 0.24 0.14 0.27 0.87 0.25 0.33 0.61 1.00 0.43 
rs4804803 A 0.47 0.50 0.52 0.50 0.49 0.77 0.15 0.67 0.17 0.28 0.37 0.93 0.36 
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1This marker deviated from HWE in the controls: rs874627 (p<1.00x10-3). 2These markers had significant deviations (p value ≤ 0.05) from HWE 
in one of the HIV groups: rs874627 (control group p < 1.00x10-3; HIV-1 p = 0.002: HIV-2 p < 1.00x10-3), rs2255301 (all HIV group p = 0.01; 
HIV-2 p = 0.01), rs1045261 (all HIV group p = 0.01; HIV-2 p = 0.04); rs1055141 (all HIV group p = 0.04; HIV-2 p = 0.02), rs8105483 (all HIV 
group p = 0.04), rs2071081 (HIV-1 p = 0.02), and rs3213427 (HIV-2 p = 0.001). 3MA-minor allele 4MAF-minor allele frequency * In bold are all 
statistically significant associations (p≤0.05). Associations with HIV-2 and dual infection should be interpreted with caution based on the small 
sample size for these groups and because rs874627 was out of HWE in both cases and controls (although this may be due to chance). 
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Supplemental Table 4.  Haplotype analyses in HIV-1 vs. control group 
Outcome Haplotype 
Global
p 
Value 
Markers
Relative Frequency 
of haplotype OR [95% CI] p Value
HIV-1 Control Group 
HIV-1 
CD209 
rs8105483-rs2287886-rs4804803 
 
0.03 G-G-G 0.32 0.31 (Baseline) - - 
 C-G-A 0.31 0.23 1.29 0.87-1.89 0.18 
 C-A-A 0.20 0.24 0.82 0.55-1.23 0.32 
 C-G-G 0.14 0.21 0.67 0.43-1.03 0.06 
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Supplemental Figure 1.  CD4 HIV-2 subgroup and control haplotype linkage disequilibrium (r2 and D’) plots 
A. CD4 control group D’ B.  CD4 control group r2 
  
C.  CD4 HIV-2 D’ D.  CD4 HIV-2 r2 
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Supplemental Figure 2.  CD209 HIV-1 and HIV-2 subgroup and control haplotype linkage disequilibrium (r2 and D’) plots 
A.  CD209 control group D’ B.  CD209control group r2 C.  CD209 HIV-1 D’ D.  CD209 HIV-1 r2 
    
E.  CD209 HIV-2 D’ F.  CD209 HIV-2 r2 
  
 
